| Title |
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2013
|
| DOI | 10.2147/dddt.s32331 |
| Pubmed ID | |
| Authors |
Vinay S Eligar, Stephen C Bain |
| Abstract |
Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose reductions. Overall, cardiovascular outcomes are no different from other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in clinical practice and emphasized its use in various stages of chronic kidney disease. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hungary | 1 | 1% |
| Unknown | 71 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 24 | 33% |
| Student > Master | 7 | 10% |
| Other | 6 | 8% |
| Student > Postgraduate | 6 | 8% |
| Researcher | 5 | 7% |
| Other | 12 | 17% |
| Unknown | 12 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 31% |
| Medicine and Dentistry | 15 | 21% |
| Agricultural and Biological Sciences | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Nursing and Health Professions | 4 | 6% |
| Other | 5 | 7% |
| Unknown | 15 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 December 2013.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,299
of 2,254 outputs
Outputs of similar age
#153,804
of 210,451 outputs
Outputs of similar age from Drug Design, Development and Therapy
#23
of 41 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,451 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.